BRAF and neoplasm: BRAF-targeted therapy alone provides limited durable disease control (154) but creates favorable effects in the tumor microenvironment; these effects include increased antigen and HLA expression, increased T-cell infiltrate, reduced immunosuppressive cytokines, and improved T-cell function (155).